ImmunityBio, Inc. (NASDAQ:IBRX) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lessened its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 0.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,840,918 shares of the company’s stock after selling 5,757 shares during the quarter. Geode Capital Management LLC owned about 0.55% of ImmunityBio worth $9,835,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of IBRX. Stephens Inc. AR acquired a new stake in shares of ImmunityBio in the fourth quarter worth $26,000. Cibc World Markets Corp purchased a new stake in ImmunityBio in the fourth quarter valued at $35,000. Virtu Financial LLC acquired a new stake in ImmunityBio during the 3rd quarter worth about $51,000. Maia Wealth LLC purchased a new position in shares of ImmunityBio during the 4th quarter valued at about $37,000. Finally, Schechter Investment Advisors LLC acquired a new position in shares of ImmunityBio in the 4th quarter valued at about $38,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Price Performance

Shares of NASDAQ IBRX opened at $2.69 on Thursday. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -2.92 and a beta of 0.51. The company’s 50-day simple moving average is $2.90 and its 200-day simple moving average is $3.48. ImmunityBio, Inc. has a 52-week low of $2.28 and a 52-week high of $10.53.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analyst estimates of $8.74 million. Equities research analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IBRX has been the subject of several recent research reports. BTIG Research began coverage on ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a report on Wednesday, April 16th. Finally, D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a report on Wednesday. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $12.19.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.